Results from phase II trials of two HER2-targeting agents, the antibody–drug conjugate trastuzumab deruxtecan and the HER2-targeting tyrosine kinase inhibitor poziotinib, indicate promising efficacy that could lead to new standards of care for HER2-mutant non–small cell lung cancer.

©2021 American Association for Cancer Research.
2021
American Association for Cancer Research.
You do not currently have access to this content.